QuantuMDx - Changing healthcare, Globally

QuantuMDx Group Logo
Q-POC™
Tackling humanitarian
health priorities
Malaria, TB & HIV diagnosis and drug resistance status for a few dollars
Q-POC™
The Handheld Laboratory
15 minute disease diagnosis at the
touch of a button
Q-POC™
Personalising Medicine
Right first time prescribing for your patients
Q-POC™
Digitizing Biology
Translating DNA the code of life into binary code
Q-POC™
One Device,
Endless Possibilities
Flexibility to extract and analyse DNA from most sample types
Our Commercial testing laboratory
One Device, Endless Possibilities™
Q-POC™: The Handheld Laboratory

Q-POC™ - analysing DNA in under 15 minutes.
The smartphone-like device will provide the accuracy,
sensitivity and specificity of a state of the art laboratory,
at the patient's side and at a fraction of the cost.

QuantuMDx - News

  • Double honours as QuantuMDx CSO named ‘Pioneer’ and CEO a ’Biobusiness Mover & Shaker’

    8 December 2014. Newcastle upon Tyne, UK Emerging British medical device developers QuantuMDx received double honours this week as CSO Jonathan O’Halloran was named ‘Pioneer’ by Connected World for his Internet of Life vision, while CEO Elaine Warburton OBE was named a ‘BioBusiness Mover & Shaker’ by BioBeat in a report on women bringing better health to people around the world.

    Jonathan and Elaine co-founded QuantuMDx in 2008, driven by their belief that quality diagnostics is an innate human right. The company is developing a connected device named Q-POC™ that will take a sample (such as blood, sputum or tumour) and provide a DNA-based diagnostic result within 15 minutes for a few dollars by the patient’s side.

    Both Elaine and Jonathan were commended for their determination, drive and passion. Connected World noted that “Jonathan O’Halloran is lucky in that he uses the words ‘job’ and ‘hobby’ interchangeably. O’Halloran is also lucky in that successfully delivering his ‘hobby’ could save millions of lives.” Elaine is driven by years of observing health inequality globally, while nursing on the wards and later running hospitals.

    Elaine Warburton OBE said “I am honoured to be included in BioBeat’s list of influential women pushing boundaries and asking more from our healthcare systems. Hopefully this will encourage more women to innovate to deliver solutions to current and future humanitarian health challenges.”

    Jonathan O’Halloran said “This (technology) is an incredible achievement and is the culmination of 10 years work and the realisation of a vision that I had whilst ‘playing’ with technology in a lab I built in my garage”.

  • FIND and QuantuMDx partnering to developing breakthrough technology for tuberculosis detection and drug resistance determination

    24 October 2014. Geneva and Newcastle upon Tyne, UK FIND, a Geneva-based non-profit organization and QuantuMDx Group, a British medical device developer are joining forces in developing a paradigm changing solution for the combined detection of and drug susceptibility determination for the causative agent for tuberculosis. Based on the molecular detection of an extensive set of genetic markers by the simple handheld Q-POC™ device developed by QuantuMDx, the time for full antimycobacterial resistance profiling will be reduced from weeklong to less than half an hour. The uniqueness of the nanowire technology developed by QuantuMDx provides the potential to interrogate the bacterial genome with unprecedented precision, as it allows not only targeted detection of specific markers, but in addition (in a future evolution of the present system) genetic sequencing on the same technology platform. As part of this partnership, FIND is supporting the development of an appropriate and integrated sample handling compartment, while QuantuMDx continues its platform development.

    Catharina Boehme, FIND’s CEO notes that ‘after an extensive screening of different Point-of-Care platform solutions amenable to the decentralized testing for tuberculosis, we concluded that QuantuMDx’s Q-POC™ system provides a unique set of capabilities which allows for the seamless integration of future genetic discoveries and hence will assure a long-term sustainability of the molecular testing approach for tuberculosis.’

    Elaine Warburton, QuantuMDx’s CEO says “our strategic partnership with FIND is of immense importance to QuantuMDx as it not only affords us a wealth of experience and expertise in developing and commercializing a much needed diagnostic device for developing countries but also provides independent validation of our strongly held belief that the provision of low cost, truly point of care molecular analysis for speciation and drug susceptibility status is a practical and effective tool in helping support the early identification and eventual eradication of MDR-TB and other infectious disease humanitarian health challenges”.

    Jonathan O’Halloran, QuantuMDx’s CSO and Q-POC™ inventor continues “"excitingly, our partnership with FIND will support us in navigating the complexities of commercializing a diagnostic device. Furthermore, with networked Q-POCs™ deployed in the field throughout the world we will have an early warning platform to monitor novel pathogens and emerging hotspots of drug resistance in real-time; a concept we like to call the Internet of Life™".

    About FIND

    Launched in 2003, FIND is an international non-profit organization that bridges local understanding, global expertise and international partnerships to advance comprehensive diagnostic solutions and overcome diseases of poverty, including tuberculosis, malaria, sleeping sickness, hepatitis C, leishmaniasis and Chagas disease. FIND creates an enabling environment for innovative diagnostic developments through its knowledge of customer needs, its specimen banks, ‘Support for Success’ program, and accelerates market uptake of such solutions through effective interaction with health authorities and laboratory strengthening in the countries. FIND maximizes the life-saving impact of diagnostics: access to accurate treatment, disease control and eradication, efficient health care spending and empowered individuals, communities and countries.

    About QuantuMDx Group

    Launched in 2008 and headquartered at The International Centre for Life in Newcastle upon Tyne, UK with subsidiaries in the USA (Chattanooga, Tennessee) and Asia (A*Star's Genome Institute of Singapore). QuantuMDx was co-founded by healthcare professional and CEO Elaine Warburton OBE, and inventor and CSO Jonathan O'Halloran both determined to play their role in finding a solution to some of the humanitarian health challenges. The Company has developed a working prototype DNA analyzer, Q-POC™ with a number of assays in the pipeline. A big focus for the Company has been on developing front end sample prep solutions for many different sample matrices to enable whole sample to result rapid diagnosis, making Q-POC™ a truly universal handheld diagnostic device. QuantuMDx is the recipient of a number of large grants from The UK's Innovate (MDR-TB assay), The Biomedical Catalyst Fund (tumour profiler), NHS NIHR's Invention for Innovation Program (DNA sequencing biosensor) and the European Union ("NanoMal" malaria assay).

    Download Press Release

    www.quantumdx.com

    Contact: Maggie Love +44 870 803 1234

    @QuantuMDx

  • Find news about QuantuMDx GroupQuantuMDx announce prototype handheld lab for 15 minute DNA-based diagnosis

    10 September 2014. TEDMED 2014, San Francisco, CA At the TEDMED 2014 conference, medical device developers QuantuMDx Group announced the successful production of their first fully-integrated sample-to-result working prototype of Q-POC™, a handheld lab that delivers your DNA-based medical diagnosis in minutes.

  • The Group believes the future of disease management and drug resistance monitoring is networked geo-stamped data, a functionality provided by the handheld Q-POC™ device. Rapid and low cost testing will enable continuous monitoring of disease and antimicrobial resistance throughout populations, as well as surveillance for emerging novel pathogen threats such as Ebola.

  • Thousands of Q-POC™ devices worldwide will use anonymized disease data to create an early warning system which will contribute to the prevention of pandemics, as well as the containment and management of drug resistance. This global network of devices will enable true personalized medicine at the individual level, and real-time public health at the national or global level.

  • This prototype brings the Group one step closer to realizing their vision, which they've named the Internet of Life™.

  • Knowledge is power

  • Q-POC™ inventor Jonathan O'Halloran said "The Internet revolutionized how we share knowledge, and the Internet of Things is changing how we interact with everyday objects. The Internet of Life will transform how we monitor and manage disease.

  • With genetic data at their fingertips, frontline healthworkers will be able to provide personalized healthcare, no matter where they are; public health officials will have the information they need to mobilize the right resources to the right place at the right time; researchers will be better equipped to monitor the efficacy of a disease intervention. Due for commercialisation in 2016, Q-POC™ is the Bio-API™ that will make this possible by translating genetic code to binary."

  • QuantuMDx at TEDMED 2014

  • QuantuMDx is participating in The Hive, an informal social environment featuring the innovative ideas that can transform health and medicine in conjunction with TEDMED 2014, the annual multi-disciplinary gathering where leaders from all sectors of society come together to explore the promise of technology and potential of human achievement in health and medicine.

  • CEO Elaine Warburton OBE said "It felt right to announce our ground-breaking prototype at TEDMED, with this year's theme of unlocking imagination in health and medicine. Many said that our vision for Q-POC was impossible, and yet here we are, with a fully-integrated working prototype!"

  • "TEDMED is delighted to welcome this year's selection of leading startups and entrepreneurs to The Hive, where we will be showcasing the most exciting innovations in health and medicine," said TEDMED COO and Partner Shirley Bergin.

  • "All participants of The Hive will help drive TEDMED's ongoing conversation about the best ways to accelerate medical progress and create a healthier life worldwide."

  • For interviews at TEDMED
    Jonathan O'Halloran, CSO & co-founder
    UK HQ +1 415 941 8183
    jonathan.ohalloran@quantumdx.com

    Maggie Love, Marketing Exec,
    +44 7584 504 327
    maggie.love@quantumdx.com


    About Q-POC™ and the Internet of Life™
    Jonathan O'Halloran presented our vision for the Internet of Life™ to audiences at Wired Health this year.
    You can view the full talk here.


  • To run DNA analysis using Q-POC™, healthworkers will simply
    1. Insert a sample, such as a drop of blood, sputum or even tumor tissue
    2. Input patient data
    3. Press go In less than 15 minutes, a healthworker will receive a diagnostic result. The device automatically carries out sample preparation, DNA extraction, amplification and detection. This video follows a sample on its journey through Q-POC™.

  • Find news about QuantuMDx Group QuantuMDx CMO Prof Sir John Burn appointed to NHS Board of Directors

    30 June 2014, Newcastle upon Tyne. UK

    QuantuMDx is delighted to announce that Chief Medical Officer Prof Sir John Burn has been appointed as a non-executive director of NHS England. Sir John is a senior clinical geneticist and academic based in Newcastle upon Tyne, with a passion and vision for bringing innovative technologies into mainstream use. Sir John's position as non-executive director of NHS England will take effect from 1 July 2014 for a period of 4 years. He, Noel Gordon and David Roberts join an existing group of six non-executive directors. He holds the NHS Endowed Chair in Clinical Genetics at Newcastle University and as well as being a distinguished academic and clinician, Sir John is also a clinical entrepreneur with two start-ups under his belt as well as a co-founder of QuantuMDx Group. He is also an accomplished drummer.

    Among many notable non-clinical achievements Sir John conceived and helped to bring to fruition the Millennium Landmark International Centre for Life in Newcastle where scientists from academia, the NHS and SMEs work side by side and the public can enjoy the interactive science museum as well as enjoy a glass of wine al fresco in the vibrant bars and clubs co-located. QuantuMDx relocated its HQ from London to Newcastle in 2011 and has since enjoyed rapid growth in the City that is now billed as the UK's Silicon Valley.

    QuantuMDx CEO Elaine Warburton OBE said "We are absolutely thrilled for John. This appointment is so well deserved. As one of the NHS's most loyal supporters he will bring to the Board years of clinical experience mixed in with his innate ability to readily translate the complexities of modern medicine into 'layman's language' at a time when the NHS is embracing great change including adopting new technologies and services. With John's appointment along with the new CEO Simon Stevens and Chairman Sir Malcolm Grant, I have no doubt that NHS England is in good hands".

  • Find news about QuantuMDx Group QuantuMDx closes $8.42m investment round for prototyping handheld MDx device

    June 2 2014, Newcastle, UK

    Handheld molecular diagnostics device pioneer QuantuMDx Group announced it had closed an $8.42m funding round it syndicated with philanthropist private investors and the University of Newcastle upon Tyne following the recent publicity success of its Indiegogo crowdfunding campaign.

    The funds will be used to further optimize and trial Q-POC™, QuantuMDx's handheld DNA sequencing & genotyping device, in addition to extending the Company's assay pipeline, expanding its research teams and appointing an Advisory Board.

    Elaine Warburton CEO and Co-Founder says "2014 will be an immensely exciting year for QuantuMDx as we demonstrate, in real-time, our ability to undertake 15 minute sample-to-result analysis for complex molecular diagnostics. Later this year when we formally unveil our prototype, we anticipate much interest from Life Science and Pharma companies seeking a low cost, high quality POC platform for diagnostics and to support drug development. Furthermore, we're now looking to appoint a number of high quality, commercially minded but fun people onto our research team and also a number of key opinion leaders onto our Advisory Board."

    "Most of the basic research was completed last year and we moved into an engineering phase to integrate these technologies and chemistries at the beginning of this year. We are now moving into the testing phase of our alpha prototype," says Jonathan O'Halloran, CSO, inventor and Co-Founder. "Excitingly, we envisage these devices to be readily distributed globally due to their low cost, fast turn-around times and referral standard testing. With networked devices all over the world we will have a platform to monitor emerging pathogens and drug resistance hotspots in real-time; a concept we like to call the Internet of Life™".

    Field trials will commence early 2015 for Q-POC™'s first assays in malaria speciation/drug resistance, in partnership with NGOs and hospitals in several African countries, and a companion diagnostic for warfarin within the UK's National Health Service, in anticipation of a commercial launch later in 2015.

    About QuantuMDx Group

    QuantuMDx Group is one of the most exciting biotechs to emerge from the UK and is developing a low cost, simple-to-use, handheld laboratory for 15-minute diagnosis of disease at the patient's side, for commercialisation in 2015. The robust device, which reads and sequences DNA and converts it into binary code using a tiny computer chip, is ideally suited to help address the humanitarian health burden by offering molecular diagnostics at a fraction of the price of traditional testing.

    Rapidly & accurately detecting and monitoring emerging drug resistance of infectious diseases such as malaria, TB and HIV will enable health professionals to immediately prescribe the most effective drug against that disease. Once the device has passed regulatory approval, it will be available in developed countries for infectious disease testing and rapid cancer profiling and, in time, be available over-the-counter at pharmacies.

    Headquartered at The International Centre for Life in Newcastle, UK with subsidiaries in the USA (Chattanooga) and Asia (A*Star's Genome Institute of Singapore), QuantuMDx was co-founded by Elaine Warburton, inventor and CSO Jonathan O'Halloran and CFO Julian Warburton. Fellow Board members include CMO Professor Sir John Burn, COO Dr Sam Whitehouse and President of QuantuMDx USA Paul Fitzpatrick. Prof Sanjeev Krishna chairs the Infectious Disease Advisory Committee.

    QuantuMDx has received numerous awards for innovation and is the recipient of a number of large grants from The UK's Technology Strategy Board (TB diagnostic), The Biomedical Catalyst Fund (tumour profiler), NHS NIHR's Invention for Innovation Program (DNA sequencer) and the European Union ("NanoMal" malaria diagnostic).

  • Find news about QuantuMDx Group CSO and co-founder Jonathan O'Halloran introduces his vision for the Internet of Life™ at Wired Health

    Wired Health video

  • Find news about QuantuMDx Group Investing in the future

    Newcastle, UK, 03 April 2014
    QuantuMDx are featured in an editorial on malaria elimination in the journal Nature Nanotechnology.
    View the article

  • Find news about QuantuMDx Group QuantuMDx launches crowdfunding campaign to help eliminate malaria with handheld lab

    Newcastle, UK, January 9th, 2014.

    On February 12th, QuantuMDx will launch an Indiegogo crowdfunding campaign to support the humanitarian health challenge to eradicate malaria by further developing and trialing their 15-minute malaria/drug resistance test using their handheld laboratory.

    With one child dying every minute of malaria, the funds raised will be used to further expand clinical trials of the Company's malaria diagnostic to allow health workers to tackle drug resistance. With no need for clean water or stable electricity, QuantuMDx's rugged and user-friendly handheld lab will offer a technology leap to developing nations, giving even the most rural communities access to life saving diagnostics.

    CEO Elaine Warburton OBE said "Our crowdfunding campaign is unique. Not only are we looking for contributors to support this phenomenally worthy cause to help save many hundreds if not thousands of children's lives, but we're also offering everyone the chance to leave a lasting legacy in the fight against malaria by contributing their winning ideas to the look and feel of our device and to take part in re-naming it from the current research name of Q-POC™. Who knows, perhaps we'll find the next Jonathan Ive? "

    CSO Jonathan O'Halloran said "We have spent years developing our tech and we now have a prototype device that has completed a sample-to-result malaria DNA test in under 15 minutes. Contributions will help take our life saving device from the lab to the field and directly save lives. We have health workers around the world crying out for our technology and are now receiving the support of major NGOs, we just need help to finalize our development and drive the technology through clinical trials."

    The Company will be releasing a series of trailers of the campaign to introduce the technology on their YouTube channel; www.youtube.com/QuantuMDxTV.

    About QuantuMDx Group

    QuantuMDx Group is one of the most exciting biotechs to emerge from the UK and is developing a low cost, simple-to-use, handheld laboratory for 15-minute diagnosis of disease at the patient's side, for commercialisation in 2015. The robust device, which reads and sequences DNA and converts it into binary code using a tiny computer chip, is ideally suited to help address the humanitarian health burden by offering molecular diagnostics at a fraction of the price of traditional testing.

    Rapidly & accurately detecting and monitoring emerging drug resistance of infectious diseases such as malaria, TB and HIV will enable health professionals to immediately prescribe the most effective drug against that disease. Once the device has passed regulatory approval, it will be available in developed countries for infectious disease testing and rapid cancer profiling and, in time, be available over-the-counter at pharmacies.

    Headquartered at The International Centre for Life in Newcastle, UK with subsidiaries in the USA (Chattanooga) and Asia (A*Star's Genome Institute of Singapore), QuantuMDx was co-founded by Elaine Warburton, inventor and CSO Jonathan O'Halloran and CFO Julian Warburton. Fellow Board members include CMO Professor Sir John Burn, COO Dr Sam Whitehouse and President of QuantuMDx USA Paul Fitzpatrick. Prof Sanjeev Krishna chairs the Infectious Disease Advisory Committee.

    QuantuMDx has received numerous awards for innovation and is the recipient of a number of large grants from The UK's Technology Strategy Board (TB diagnostic), The Biomedical Catalyst Fund (tumour profiler), NHS NIHR's Invention for Innovation Program (DNA sequencer) and the European Union (NanoMal malaria diagnostic).

    Press enquiries:
    Maggie Love
    Tel: +44 (0) 870 803 1234
    Email: maggie.love@quantumdx.com

  • Find news about QuantuMDx Group CEO Elaine Warburton receives an OBE for services to health innovation

    Newcastle, UK,1st January 2014:

    QMDx are delighted to announce our CEO Elaine Warburton receives an OBE for services to health innovation!
    More to follow...

  • Find news about QuantuMDx Group DNA testing company NorthGene is added to the Ministry of Justice accredited list

    Newcastle, UK, 22 October 2013

    NorthGene Limited, one of the UK's first commercial DNA testing companies has received notification from the Ministry of Justice that their laboratory is now accredited to carry out scientific tests for parentage where the court gives a 'Section 20 direction'.

    NorthGene recently achieved UKAS accreditation for ISO 17025 allowing them to perform legal DNA tests. The company's testing laboratory is based within the world renown genomics hub at The International Centre for Life, Newcastle, UK where the company currently undertakes legal relationship testing for many coroners, family law solicitors, local councils and the general public alongside other legal testing including drug and alcohol testing.

    This new accreditation recognises NorthGene's exceptional standards of quality and laboratory & customer services and allows NorthGene to not only perform paternity, maternity and siblingship tests for legal reasons such as changes in birth certificates, inheritance cases and identification of unknown bodies for coroners but also Ministry of Justice court directed cases and parentage tests for immigration applications.

    This accreditation will enable the company to further expand their in-house testing portfolio and embrace additional Forensic DNA testing services for the legal system.

    Managing Director Marie Whitehouse commented, " We are delighted to be one of the very few UK based accredited laboratories able to perform DNA testing tests on behalf of the Ministry of Justice. The NorthGene Team prides themselves on an exceptional quality of service and the ability to really understand and accurately interpret the complexities surrounding DNA analysis. NorthGene is privileged to be under the expert guidance of Prof Sir John Burn, Chief Medical Officer, who provides excellent analysis and training for our more complex cases and can also perform as an expert witness in court if required."

    About NorthGene Limited NorthGene Limited was established in 1996 by Professor Sir John Burn, an internationally renowned human genetics specialist and medical consultant. Sir John is Professor of Clinical Genetics at Newcastle University and sits on various genomics advisory boards for the NHS and government including the Genomics Strategy Board and the Human Variome Project. Based within The International Centre for Life, Newcastle Upon Tyne, NorthGene is part of The QuantuMDx Group of Companies and delivers customer focused, gold standard commercial DNA and molecular testing to UK and overseas customers.

    Download Press Release
  • Find news about QuantuMDx Group QuantuMDx awarded £1m grant to develop rapid multi-drug resistant TB test for their smartphone-like device

    Newcastle, UK, 20 October 2013

    British biotech QuantuMDx has been awarded a UK government's Technology Strategy Board (TSB) grant to develop Q-TB™, a rapid and cheap test that will analyse sputum samples at the patient's side and diagnose multi-drug resistant TB (MDR-TB) within 15 minutes enabling immediate personalised prescription of the most effective TB drug treatment.

    TB causes 2m deaths every year despite most cases being curable. The disposable Q-TB™ cartridge will be used on Q-POC™, QuantuMDx's universal handheld diagnostic device and provide a technology leap for both developing nations which lack healthcare infrastructure and the overburdened healthcare systems of developed nations which are seeing an re-emergence of MDR-TB, particularly within inner cities.

    The three year £2m project will integrate QuantuMDx's state of the art DNA analysis device with a novel sputum disruption technology and a comprehensive TB biomarker panel developed by St George's, University of London and its partners. The project is particularly strong as it also embraces the expertise of various global academic TB Groups and several TB focused charities and NGOs who are currently working in the field to help eradicate the disease and who understand, first hand, what is needed for a rapid TB diagnostic.

    The state of the art device will enable doctors, nurses and health professionals alike to perform complex testing that will guide prescription of targeted drug treatments. The patient's sputum sample is automatically prepared in a specially designed sample cup, which is then integrated in a closed system with the device's disposable test cartridge. With the press of a single button, the device will automatically extract, amplify and detect the TB DNA using a range of innovative lab-on-a-chip technologies, providing a diagnostic and drug susceptibility result in under 15 minutes. QuantuMDx's Chief Scientific Officer and co-founder Jonathan O'Halloran said "Currently MDR-TB diagnostic and drug resistance testing is carried out in slow, expensive referral or satellite laboratories. By the time results are returned weeks or months later, the patient is often lost to the system. The only way we can effectively treat and prevent the spread of MDR-TB is to perform rapid testing at the patients' side, enabling the immediate prescription of targeted drug treatments. Our robust handheld device is ideal for use in field settings, and is responsive to the addition of hundreds, even thousands, of new markers of disease as these are discovered thus providing a one-stop future proofed testing device meeting the testing needs of communities worldwide." The Q-TB cartridge will be the fourth assay to be developed for use on QuantuMDx's Q-POC™ universal handheld diagnostic device. Other tests in development include a malaria speciation and drug resistance assay, a warfarin dosing companion diagnostic and a tumour profiler.

  • Find news about QuantuMDx Group QMDx recognized for Medical & Life Sciences innovation at Made in the North East Awards

    Newcastle, UK, October 3, 2013:

    QuantuMDx Group Limited, a pioneering biotech company based at The Centre for Life in Newcastle upon Tyne, was awarded the Insider's 'Made in the North East' Life Sciences trophy in recognition of its ground-breaking handheld DNA sequencer that will be able to rapidly diagnose disease both in developing and developed countries, in minutes and for a fraction of the price of traditional lab based diagnostics.

    Chief Operating Officer Dr Sam Whitehouse and Research Manager Dr Jonathan Salmon were presented with the Medical & Life Sciences Award in recognition of the impact this medical device will have on global medicine at its commercial launch anticipated in 2015. QuantuMDx's low cost handheld device carries out DNA analysis on any sample, such as blood, spit or even tumour tissue, and provides disease diagnosis in under 15 minutes by a patient's side. Tests are currently in development for cancer, malaria, TB, a panel of common STIs and correct warfarin dosing.

    The Company is currently working with some of the most influential academic, industrial and charitable organisations across the world to introduce the device into resource scarce settings in Africa, India and the BRICS nations as well as into the NHS and hospitals and clinics in developed countries.

    Dr Whitehouse said "To see our achievements rewarded by Insider and the North East community is a testament to not only to our cutting edge technology but to our dedicated team, working hard to make our vision of democratizing global healthcare a reality. Many fellow North East businesses were astounded to learn that something so advanced could be made by a small company right here in Newcastle upon Tyne. It was wonderful to see the variety and quality of manufacturing expertise in the area, and we're proud to be recognized as a jewel in the crown of this vibrant community."

    As a regional winner QuantuMDx Group will now be shortlisted for the 2014 International Festival of Business awards due to take place in Liverpool next year.

  • Find news about QuantuMDx Group Press Release - QuantuMDx to run Great North Run for Bowel Cancer UKs


    View Press release on Great North Run

    Newcastle-based diagnostics company QuantuMDx Group will take on the UK's most popular half marathon on September 15 when a team of Directors and staff run the Great North Run for Bowel Cancer UK. Chief Scientific Officer and co-founder Jonathan O'Halloran chose to support the charity after a close relative and friend were diagnosed with bowel cancer, and he encouraged his co-workers to join.

    Bowel cancer is the UK's second biggest cancer killer but many people are still unaware of the symptoms. Every year, over 40,000 people are diagnosed with bowel cancer and more than 15,700 people die of the disease. Jonathan's uncle and his best friend's father were both diagnosed with bowel cancer this year which spurred him on to take part in the race and fundraise for Bowel Cancer UK.

    Bowel cancer will be one of many common cancers QuantuMDx's handheld diagnostic device will diagnose in under 20 minutes. Jonathan and his business partner Elaine Warburton, who herself lost her mother to cancer, started the company six years ago in his garage lab, and it has since grown to a 37-man team based in the International Centre for Life.

    Jonathan said: "The effects it had on my peer group and my family after discovering they both had bowel cancer has been enormous, it truly knocked us for six. Fortunately we have a very good support system and as I am researching in the field I was able to inform and help guide the families through their difficult time with a lot of help from the information on the Bowel Cancer UK website. In addition to my work at QuantuMDx, participating in the Great North Run for Bowel Cancer UK will be an extra way for me to give something back." Jonathan along with Elaine and their colleagues Sam Whitehouse, Jonathan Salmon and Joseph Hedley will also be running to raise money for Bowel Cancer UK, and colleagues Marc Flanagan, Mohit Devgan and Maggie Love will also be running.

    For further press information, pictures of the guide or for a Bowel Cancer UK spokesperson, please contact Julia Kouyoumdjian or Grant Imlach in Bowel Cancer UK's Press Office on 020 7940 1776 or press@bowelcanceruk.org.uk

    Notes to Editors: About Bowel Cancer UK Bowel Cancer UK aims to save lives and improve the quality of life for all those affected by bowel cancer. If you have concerns call the Bowel Cancer Information and Support Service on free phone 0800 8 40 35 40 or email support@bowelcanceruk.org.uk for more information about bowel cancer, please visit www.bowelcanceruk.org.uk About Bowel Cancer Bowel Cancer is the second most common cause of cancer death in the UK, affecting both men and women. Every year over 40,000 people are diagnosed with bowel cancer and more than 15,700 people die of the disease. About Bowel Cancer Symptoms Symptoms of bowel cancer include: Bleeding from the bottom and/or blood in your poo. A change in your normal bowel habit lasting three weeks or more especially to looser or runny poo. Extreme tiredness for no obvious reason. Unexplained weight loss. A pain or lump in your tummy.

    View Press Release
  • Find news about QuantuMDx Group Article - Fighting malaria requires new diagnostic tools

    The Conversation
    Published: June 25, 2013


    Malaria hits rural dwellers in poor countries the hardest. Those bitten by the wrong mosquito often do not know for many days that they have contracted malaria. Some have little or no access to doctors. There are times when, even if the tests confirm the disease soon enough, standard treatments may not help because they may be suffering from the drug-resistant strain of the parasite.

    The World Health Organisation recommends diagnosis of malaria before treatments are begun, because if drug-resistant varieties are on the rise. Despite support from big funding agencies, such as the Global Fund to fight AIDS, Tuberculosis and Malaria, such diagnoses are not happening often enough.

    With more than 200 million cases and over 660,000 deaths reported annually, the need to develop a more reliable, cheap and effective tool to detect malaria without the need for trained personnel has never been higher.

    Rapid diagnostic tests (RDTs) developed for malaria in recent years have made it much easier to diagnose without using the conventional method of staining blood films and then examining them under a microscope.

    RDTs still suffer from limitations, though. They need trained personnel to generate reliable results. Even though these test can be performed without the need for electricity, other field conditions such as high ambient temperatures encountered during transport and storage can interfere with the quality of results.

    Access to trained personnel in rural places is difficult. Could we develop a method that does not require trained personnel? A recent large-scale experiment suggests we can. In the experiment, 1000 untrained individuals across 60 countries were able to diagnose malaria as accurately as experts.

    There are a number of efforts to build better diagnostic tools. For example, a group of students at Makerere University in Uganda have developed a new needleless malaria-testing application that uses a light sensor connected to a tablet device to detect the infection. This could perhaps be used to screen large groups of patients quickly before suspected infections are confirmed.

    Another tool comes from researchers at Michigan State University. They have identified a test that can determine which children with malaria are likely to develop cerebral malaria, a much more life-threatening form of the disease. Only about 1% of children with malaria develop the life-threatening form of the disease, yet thousands of African children die from it each year. One more solution

    Researchers at St. George's University of London where I work, along with researchers in Sweden and German, have been working on the Nanomal project to build another tool that could make malaria diagnosis cheap and more effective. The handheld device can diagnose malaria on-site in less than 15 minutes.

    Successful diagnosis depends on reliable and detailed results based on a patient's blood sample. Fortunately, each parasite has specific DNA markers that differentiates them. This device consists of a nanowire (billionths of a metre thick) that changes how much electricity it conducts based on which DNA marker it comes in contact with.

    The diagnosis, which can be completed in a few minutes, is made by analysing a blood sample of a patient obtained by a small prick on the finger. Parasite's DNA is then extracted from this sample and analysed by the nanowire.

    If, say, the malaria is caused by Plasmodium falciparum, then it is likely that it is a drug-resistant variety. A doctor or nurse on site can then give more personalised prescription, helping increase chances of successful treatment while also reducing the chances of drug-resistance buildup.

    The device will be tested in the field this year. If successful, the price of each device is expected to be about the same as a smartphone initially. A single-test cartridge will be around £10 to begin with.

    In addition to improving immediate patient outcomes, the project will allow the researchers to build a better picture of levels of drug resistance in stricken areas. It will also give them information on population impacts of antimalarial interventions.

    There are other challenges such as ensuring that the device can be quickly modified to include new DNA markers as more drug-resistant parasites are selected. And the price of each device and its cartridges need to be cut further, so that those in poor countries can afford it on a large scale.

    When all these tools are put together, there is great hope that they will help cut down the number of those who die from malaria every year. The sooner this happens the better.

    View the article
  • Find news about QuantuMDx Group QuantuMDx Group seek end user feedback for the development an automated DNA extraction device

    QuantuMDx Group (QMDx) is an exciting UK based medical devices company developing a suite of ground-breaking technologies that miniaturise time-consuming lab processes into rapid and accurate, low cost devices. We are currently developing our rapid sample prep and DNA extraction technology into a simple-to-use, small benchtop device. In order to ensure we take into consideration end-user needs and functionality when designing this device, we are now engaging with scientists and lab technicians to understand your requirements. Our low-cost device will extract high quality DNA from FFPE samples in under fifteen minutes, and the fully automated process requires minimal hands-on time. The sample is input, and once the paraffin and formalin are removed the cells are lysed and flowed through QMDx's novel sorbent Q-Filter which captures cellular debris, thus purifying DNA for immediate use in PCR. While our initial focus is using FFPE samples, our aim is adapt the sample reception to become multi-purpose and able to analyse other sample types such as a pinprick of blood, vial of blood, fresh tissue, faeces, urine, swab, and sputum making the device multi-purpose.

    The small device footprint, ease of use and low cost consumables will ensure that the device can be easily introduced into small labs and clinics. The disposable cassettes may be "one stop" and contain on-board all required reagents, or may require some off-cassette bulk reagents. Either way we aim to ensure that minimal time is spent on sample loading, device upkeep and cleaning. The easy-to-use, low-maintenance device will streamline workflows, reduce sample processing time and crucially provide DNA of high quality and purity.

    We would welcome your input into a survey of end user requirements and preferences. It should take less than 5 minutes to complete, and we will keep you posted with on-going device developments. Thank you for your on-going support.
    Click here to take survey

  • Find news about QuantuMDx Group Daily Express Article - £500 device can detect cancer in ten minutes

    By: Giles Sheldrick
    Published: Mon, May 27, 2013

    A BRITISH scientist working in his garage has developed a cheap, easy-to-use device that detects almost any disease or cancer in just 10 minutes.
    The hand-held gadget can micro-analyse tumours and infectious disease at lightning fast speed allowing doctors to make almost instant diagnosis while the patient waits.
    The £500 iPhone-sized Q-POC machine can also analyse the genetic signatures of the disease before advising on the best type of drugs to use.
    The device is undergoing rigorous clinical trials and could be used across the NHS as early as next year, revolutionising the treatment is administered.
    The breakthrough was made by Jonathan O'Halloran, funded by business partners Elaine Warburton and her husband.

    His device is considered so potentially important in the fight against cancer, the Government and NHS have committed significant sums towards its development.

    The first prototypes are in advanced trials and experts say they have the potential to prolong the lives of 12.7million newly-diagnosed cancer sufferers and save the lives of millions with infectious diseases.
    Mr O'Halloran, 37, who developed his thirst for science while a pupil at the Old Grammar School in Lewes, East Sussex, said: "We are using the device to extract, amplify and analyse DNA from tumours or other samples to make sure the patient gets a personalised service as soon as possible.

    "Science is my life's passion, but when I was experimenting in my garage I never dreamed we would get to a stage where we could have a diagnosis in 10 minutes. It's incredible. We see this working alongside histopathologists and clinical oncologists to provide the missing link – a personalised service for cancer sufferers. It will also provide rapid diagnosis for TB, malaria, HIV and STIs, giving doctors key information on which drugs will treat the disease.
    The idea now is to make these devices available to doctors and health professionals."

    Q-POC – which has been fully protected and patented – analyses submicroscopic amounts of human tissue to rapidly diagnose a disease or cancer by its genetic make-up and how far it has progressed or spread.

    Using his garage in Uckfield, East Sussex, as a makeshift laboratory, Mr O'Halloran hit on the ground-breaking idea of releasing DNA within a barely visible sample and making multiple copies to allow an accurate diagnosis, whether cancer mutations exist and which oncology drugs will work best.

    The invention is being developed by British company QuantuMDx Group in partnership with Newcastle University.

    Experts think it has the potential to save billions of pounds in wasted primary health care costs and wrongly prescribed medicines.

    A Department for Health spokesman said last night: "Detecting cancer early is vitally important.
    "We welcome the development of any new and innovative technology which could potentially help save lives."

  • Find news about QuantuMDx Group Director, Sir John Burn writes in the British Medical Journal

    Should we sequence everyone's genome? Yes

    BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f3133 (Published 21 May 2013) Cite this as: BMJ 2013;346:f3133

    Author: John Burn, Professor

    As technological prowess soars and costs plummet, is the era of personalised medicine now in sight? John Burn says sequencing everyone's genome would give us unparalleled knowledge to prevent, diagnose, and treat disease, but Frances Flinter (doi:10.1136/bmj.f3132) thinks there are serious ethical implications

    We should all have our genomes sequenced. In 1986 our 5 year old son planted a conker in our back yard. He explained that he wanted a tree house so needed a tree. The tree is now ready to receive boarders, though they will be from our family's next generation. The Human Genome Project began at about the same time with similar high aspirations: to deliver personalised medicine to generations to come.

    That time is now upon us. The cost of gene sequencing has fallen 10 000-fold in a decade, with another drop by an order of magnitude expected soon. Setting aside the considerable but surmountable challenges associated with large segments being duplicated or deleted and stretches of hard to sequence repeats, we can have a whole genome for the price of a family package holiday. Even now, bulk sequencing all 20 000 "genes," the exome, costs less than £500 (€590; $770).

    The Human Genome Project depended on British discovery, particularly the work of the Wellcome Trust's Sanger Institute. No one can match our capacity to do "genetic medicine" in a coordinated healthcare system at scale. This is why the UK government has committed £100m to pump prime sequencing of 100 000 whole genomes in the NHS. Only by analysing sequence data and phenotypes across large patient populations will we understand which bits of genetic information are clinically relevant. We can and should lead the world in showing how to put genetic knowledge into patient care safely and effectively.

    Responsible use

    Genetic predisposition plays a central role in most common diseases. It is the primary cause of most of the rare diseases that collectively afflict 1 in 17 people.1 Clinically relevant discoveries are entering practice at a rate of more than 30 a month.

    And the provisos? First do no harm. Our capacity for interpretation is still rudimentary so we must have explicit consent to retain sequence data linked to patients' records. Our population trusts the health service to deliver healthcare to all in need, regardless of their genetic predispositions. We must keep that principle safe along with the sequence data. That doesn't preclude partnership with the pharmaceutical and biotechnology industries: we need them to expand the exciting list of drugs that can target genetic subgroups and give us the gadgets and biomarker algorithms to find them.

    As we leave the high ground of "single gene disease," such as hereditary cancers and cardiomyopathies, we risk drowning in data and doing harm. Offering volunteers at risk of monogenic disorders an effective service in return for them allowing their genomes to be pooled and data mined is straightforward. Systematic gathering of genomic information where there has been no request, and any sequence variation discovered lacks clinical use, is more challenging if consent and follow-up counselling are to be effective.

    Each one of us carries, perhaps, three million sequence variants, of which about 400 contribute to disease predisposition,2 and one or two would cause a severe recessive disease if both partners pass them to a child. The bioinformaticians need to know it all to develop robust diagnostic algorithms.

    But patients do not. We must not dump heaps of molecular uncertainty on patients, families, and their carers. In Nijmegen, the Netherlands, teams of geneticists try to interpret exomes of patients provided by clinicians, passing on (with explicit consent) only information about variants of known relevance plus "incidental" findings of obvious importance (H G Brunner, personal communication).

    Personalised treatment

    Genomics is not just about rare syndromes and predisposition to disease. It underpins huge variation in our capacity to metabolise drugs, often leading to serious adverse events, but this is ignored. At the moment everybody gets the same size shoes and they are asked to hobble back next week if they don't fit. We have known for decades many of the simple genetic variants responsible for such adverse events. We write more than half a million prescriptions for warfarin each year, knowing that three genetic variants can help quickly to reach the individual dose, cutting attendances and adverse events; yet still we just guess.3 Widespread sequencing linked to outcomes will expand such knowledge considerably.

    I remain sceptical of an early transition to providing our genome as part of our electronic medical records. The sequences we can provide now are not sufficiently complete, and safe storage and access present challenges.

    When it costs only £100 we can run the sequencers more than once, extracting necessary information and discarding the rest. In some situations we will be able to reduce the question to a genetic test at the point of care.

    I am part of a team that's been working for five years on using nanowires to analyse nucleic acids.4 We are about to test disposable cassettes that will extract, amplify, and perform specific tests such as drug sensitivity in under 15 minutes for under £20. The next step will be to provide whole genomes. Others are also innovating in this field. Whoever wins the race, the strong probability is a mixed economy of stored whole genomes, disposable sequencing in hospitals, and cheap, fast genotype panels in some frontline care settings. The net result will be accurately targeted diagnosis, treatment, and prevention.

    Genomics extends beyond identifying predisposition to disease. Linking whole genome sequencing to clinical outcomes will influence drug discovery and development—for example, the BRAF gene inhibitor vemurafenib to treat melanoma was developed only a decade after the cancer genome project identified the target.5 And the tools developed from human genomics will transform another battlefront—routine high speed sequencing of pathogens will expose their weaknesses within hours, revolutionising response to epidemics worldwide.

    Meanwhile "point of care" technology will allow drug resistance of infective agents causing diseases such as malaria to be studied in real time in the swamp. Whole genome sequencing is a technical, clinical, and societal challenge. But as Goethe said, "Whatever you do, or dream you can, begin it. Boldness has genius and power and magic in it."

    1. 1. Chief Medical Officer. The 2009 annual report of the chief medical officer. Department of Health, 2010.
    2. 2. Xue Y, Chen Y, Ayub Q, Huang N, Ball EV, Mort M, et al. Deleterious and disease allele prevalence in healthy individuals: insights from current predictions, mutation databases, and population-scale resequencing. Am J Hum Genet2012;91:1022-32.
    3. 3. Anderson JL, Horne BD, Stevens SM, Woller SC, Samuelson KM, Mansfield JW, et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualising warfarin dosing (CoumaGen II) Circulation2012;125:1997-2005.
    4. 4. Cui Y, Wei QQ, Park HK, Lieber CM. Nanowire nanosensors for highly sensitive and selective detection of biological and chemical species. Science2001;293:1289-92.
    5. 5. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med2012;366:707-14.

  • Find news about QuantuMDx Group QuantuMDX, GIS to Develop Asian Population-Specific Test for Cancer; More Assays Planned

    Read Article

  • Find news about QuantuMDx Group 20th May 2013 | QuantuMDx and Genome Institute of Singapore announce collaboration to develop Asia-specific assays on QuantuMDx's Q-POCTM First test to direct treatment of chronic leukemia and lung cancer

    Singapore May 21, 2013: A*STAR's Genome Institute of Singapore (GIS) has signed an agreement with QuantuMDx (QMDx), a UK-based biotech developing handheld diagnostics and whole genome sequencing devices. Under this collaboration, QMDx's wholly owned Singapore-based subsidiary QMDx Asia and GIS will develop Asia-specific point-of-care genetic tests for use with Q-POCTM, QMDx's handheld point-of-care device. QMDx will commercialize the tests. The first assay from the development pipeline will direct treatment of East Asian patients with kinase-driven cancers, such as chronic myeloid leukemia (CML) and epidermal growth factor receptor-mutated non-small lung cancer (EGFR NSCLC).

    QMDx's handheld, sample-to-result diagnostic device Q-POCTM will be used to rapidly test patients, in a cancer clinic or post surgery, for the presence of a BIM deletion polymorphism genetic mutation which GIS has shown causes a patient's malignancy to be unresponsive to the standard Tyrosine Kinase Inhibitors (TKI) treatment regime. Instead, the treatment can be personalized and made more effective by switching treatment to other chemotherapeutic agents such as the promising BH3 mimetics. Q-POCTM, currently at prototype stage, utilises novel sample preparation, extraction, amplification and a nanowire biosensor to detect DNA sequences of interest in under 15 minutes, from sample to result.

    Dr Michael Rossbach, Head of Strategic Alliances at the GIS said of the collaboration, "This collaboration has the potential to be most far-reaching for the continent of Asia by harnessing the Genome Institute of Singapore's quality cancer research, focused on East Asian populations, and translating and testing our validated biomarkers for disease for use in QuantuMDx's ground-breaking sample to result point of care platform Q-POC TM. The assays can then be commercialised and utilized in a near patient setting, taking us into the realms of true personalized treatment." QMDx's Group Chief Executive Elaine Warburton said "The collaboration with GIS is of great importance to QuantuMDx and our Asia subsidiary, QMDx Asia, as it offers access to GIS's world class genomic expertise and facilities and to their Asian-specific validated disease biomarkers. This is of immense importance in developing Asian-specific diagnostic and companion diagnostic assays for sale within Asia. As part of our global drive for precision medicine using Q-POC, it is our strategy to develop disease specific panels which are developed for and validated on populations from the geographic regions in which they are sold."

    View the press release

  • Find news about QuantuMDx Group 15th May 2013 | Nanomal present handheld device for rapid detection of malaria and drug resistance at BioMalPar

    View the press release

  • Find news about QuantuMDx Group 30th April 2013 | The Guardian name Nanomal device number one innovation in combating malaria

    View the article

  • Find news about QuantuMDx Group 25th April 2013 | World-leading nanotechnology device to prevent malaria deaths through rapid diagnosis

  • A pioneering handheld device using cutting-edge nanotechnology to rapidly detect malaria infection and drug resistance could revolutionise how the disease is diagnosed and treated. Around 800,000 people die from malaria each year after being bitten by mosquitoes infected with malaria parasites.

    An FP7 European Union funded $5.2million (£4million) Nanomal project is developing a simple-to-use, affordable, handheld diagnostic device to swiftly detect malaria infection and parasites' drug resistance. The 3 year project was launched in 2012 in response to increasing signs that the malaria parasite is mutating to resist the most powerful class of anti-malaria drugs, artemisinins.

    The device will use a range of novel technologies to rapidly analyse the parasite DNA from just a finger-prick of blood. It will then provide a malaria diagnosis, speciation and drug resistance information in less than 20 minutes, allowing a course of personally tailored treatment to be given by the end of the patient's appointment. The smartphone-like diagnostic device will allow healthcare workers in remote, rural areas to deliver effective drug treatments, potentially saving lives and enabling efficient allocation of limited resources.

    Currently, malaria diagnosis is conducted either by using a microscope to look for malaria parasites in a blood sample, which gives only a yes/no answer, or by sending a blood sample to a central referral laboratory for drug resistance analysis, which is time-consuming, prohibitively expensive and requires skilled scientists. Therefore when a patient presents with a fever, drug treatments are often prescribed with either no drug resistance information, or no diagnosis at all, and may not be effective. The ability to treat effectively and immediately will prevent severe illness and save lives.

    The Nanomal consortium is being led by St George's, University of London, which is working with UK handheld diagnostics and DNA sequencing specialist QuantuMDx Group and teams at the University of Tuebingen in Germany and the Karolinska Institute in Sweden.

    QuantuMDx's CEO Elaine Warburton said: "Placing a full malaria screen with drug resistance status in the palm of a health professional's hand will allow instant prescribing of the most effective anti-malaria medication for that patient. Nanomal's rapid, low-cost test will further support the global health challenge to eradicate malaria."

    Nanomal lead Professor Sanjeev Krishna, from St George's, said: "Recent research suggests there's a real danger that artemisinins could eventually become obsolete, in the same way as other anti-malarials. New drug treatments take many years to develop, so the quickest and cheapest alternative is to optimise the use of current drugs. The huge advances in technology are now giving us a tremendous opportunity to do that and to avoid people falling seriously ill or dying unnecessarily."

    The handheld device will take a finger prick of blood, extract the malarial DNA and then detect and sequence the specific mutations linked to drug resistance, using a nanowire biosensor. The chip electrically detects the DNA sequences and converts them directly into binary code, the universal language of computers. The binary code can then be readily analysed and even shared, via wireless or mobile networks, with scientists for real-time monitoring of disease patterns.

    The device should provide the same quality of result as a referral laboratory, at a fraction of the time and cost. Each device could cost about the price of a smart phone initially, but may be issued for free in developing countries. A single-test cartridge will be around $13 (£10) initially, but the aim is to reduce this cost to ensure affordability in resource-limited settings.

    In addition to improving immediate patient outcomes, the project will allow the researchers to build a better picture of levels of drug resistance in stricken areas. It will also give them information on population impacts of anti-malarial interventions.

    Clinical trials of the device are expected to begin within three years, after which it will be brought to market. The technology could be adapted afterwards for use with other infectious diseases.

    www.nanomal.org
  • Find news about QPOC 1st March 2013 | 2013 Biomedical Award Winners- QuantuMDx and CSO hailed as "Best of the North"
    at Biomedical Awards

    QuantuMDx Group Limited, a leading UK medical devices company and CSO Jonathan O'Halloran were honoured among the
    best of the North of England's biomedical companies at the 2013 Biomedical Awards, hosted by Bionow at the BALTIC Centre
    for Contemporary Art on Gateshead Quays.

    The Company was presented with the Innovation and Technology Award, sponsored by Newcastle Science City and Newcastle Gateshead Initiative.
    QuantuMDx was recognised for its continuing development of a low cost handheld device named Q-POC™ which can take any sample, such as blood, urine, or even a tumour and use DNA analysis to diagnose disease in under 15 minutes.
    Tests are currently in development for correct warfarin dosing, cancer testing, infectious and tropical diseases testing.

    Jonathan O'Halloran CSO and co-founder of QuantuMDx was named Promising Technologist of the Year, sponsored by SRG.
    The "Biotech Rockstar" was recognised for his innovative vision and determination, which nurtured his seedling of an idea from
    a one-man garage laboratory to a 35-man multinational company with pan-global collaborations, partnerships and even its own commercial genomics lab.

    Jonathan O'Halloran said

    "Winning this award has not only been an immensely humbling experience but has been the culmination of five years' of the most amazing rollercoaster ride! With my colleagues Elaine and Julian Warburton we have woven my inventions around a rock solid commercial and financial base and taken QuantuMDx Group from my lab-in-a- garage to a pan-global medical devices company offering, in my opinion, three of the most promising diagnostic, sequencing and proteomic platforms addressing many global health challenges. With Q-POC less than a year away from commercialisation, the next twelve months will see us move to a dedicated lab and engineering complex with over 70 staff in four continents. The best is definitely yet to come!"

    QuantuMDx and Newcastle University were also shortlisted for the Partnership/Collaboration of the Year Award.
    View the press release from Bio Now

  • Find news about QPOC 5th November 2012 | Biomedical Catalyst funds "tumour profiling while you wait" based on QuantuMDx's world leading nanowire technology

    View the press release

  • Find news about QPOC 25th September 2012 | QuantuMDx Group partners with Chemical Nanoscience Laboratories, University of Newcastle to further develop Nanowire Technologies

    QuantuMDx Group Limited today announced that it has signed an agreement to work within the Chemical Nanoscience Laboratories in the School of Chemistry, Newcastle University to further develop its handheld and bench top diagnostic and sequencing devices.

    The collaboration brings together expertise in nanotechnology, surface chemistry as well as strengthening the synthetic work currently being undertaken by QuantuMDx. Under terms of the agreement, QuantuMDx shall place members of its research staff in the school and work alongside academics to develop new technologies and processes in this field. It is anticipated further projects and collaborations will develop through this unique embedded partnership model.

    Dr Sam Whitehouse, the Company's chief operating officer comments "QuantuMDx is delighted to be working with Newcastle University's School of Chemistry. Our collaboration will involve the sharing of equipment and joint applications for research funding. In addition our staff will be located in heart of the Chemistry School so as to maximise the opportunity for successful interactions promoting innovation".

    'This is an excellent example of industry-academia interaction' says Professor Mike Green, Head of the School of Chemistry. 'We are delighted to be associated with such a vibrant state of the art Company with which we have so much in common in terms of research interest'

    About QuantuMDx Group

    QuantuMDx Group is one of the most exciting medical device biotechs to emerge from the UK.  With its headquarters at the International Centre for Life in Newcastle, UK and offices in the USA, Asia and Africa, the last 5 years has seen the company grow from its humble beginnings in a South of England based 'biotech garage lab' to a multi-national company with pan-global collaborations, partnerships and even its own commercial genomics lab.

    Combining the business acumen of health professional and entrepreneur CEO Elaine Warburton with the far-reaching vision of inventor and CSO Jonathan O'Halloran and the clinical and ethical guidance of Prof Sir John Burn, the company has developed a suite of proprietary on-chip, molecular diagnostic and sequencing technologies – sample prep, DNA extraction, PCR and detection using a nanowire biosensor - which it is currently integrating into a suite of handheld and benchtop devices for rapid, accurate and very low cost assays for genomic and infectious disease applications along with its  "Last-Gen" T2T sequencer (telomere to telomere whole genome sequencing).

    About Chemical NanoScience Laboratories, University of Newcastle, UK

    Chemistry at Newcastle has a long history of pushing back scientific boundaries and focuses on the synthesis, properties, and modelling of materials with features on the low nanometre (10-9 m) length scale. Confining materials to such dimensions allows extreme miniaturization and we work to address critical scientific problems associated with their development towards applications including fundamental studies of their chemical and physical properties.

    The School of Chemistry is currently home to over 80 members of staff and over 350 students, all of who work together to ensure a vibrant community in which everyone can reach their full potential.

    For Further Information:
    QuantuMDx Contact:
    Sam Whitehouse, Chief Operating Officer
    Tel: +44 7788 230 385
    Email: sam.whitehouse@quantumdx.com

    School of Chemistry, University of Newcastle Contact:

    Professor Mike Green
    Tel. 0191 222 6786
    Email: mike.green@newcastle.ac.uk
    www.ncl.ac.uk

  • Find news about QPOC 28th September 2012 | QuantuMDx acquires North East based identity testing company NorthGene to expand commercial DNA analysis portfolio

    QuantuMDx Group Limited, one of the UK's most promising biotechs announced it has acquired the entire share capital of NorthGene Limited in a transaction involving a share swap plus cash investment. The funds will be utilised to further develop NorthGene's laboratory and staffing infrastructure, secure various laboratory accreditations and to expand the Company's test portfolio and DNA analysis services to embrace medical, veterinary and scientific research applications.

    Established for almost two decades, NorthGene has been offering commercial identity testing services to the NHS, legal services and the Public. NorthGene has historically been run as a not for profit organisation under the leadership of Prof Sir John Burn, with all monies generated invested back into medical research. Elaine Warburton, QuantuMDx's CEO says "Our aim is to continue this philanthropic philosophy of using NorthGene surpluses to invest in advancing medical research for the benefit of global health."

    NorthGene's Managing Director Marie Whitehouse comments " This is a wonderful opportunity for NorthGene to further expand our test portfolio under the guidance of the QuantuMDx's scientific, quality and commercial teams, who have access to, and extensive knowledge of, the very latest proven DNA based tests across medical and non-medical applications. In time we anticipate further supporting QuantuMDx in trials and the commercial roll-out of its ground-breaking diagnostic and sequencing devices".


  • NorthGene Limited Contact
    Marie Whitehouse, Managing Director
    marie.whitehouse@quantumdx.com
    Tel: +44 (0) 870 803 1234
    Mob: + 44 (0) 78675 531 432

    www.northgene.co.uk

  • Find news about QPOC 26th September 2012 | QMDx awarded £3.5m EU FP7 innovation grant to develop rapid point of care diagnostic for malaria and drug resistance status


    View the press release

  • Find news about QPOC 1st August 2012 | QuantuMDx Group Launches QMDx ASIA in Singapore

    QuantuMDx Group Limited today announced that it has launched a subsidiary QuantuMDx Asia Ltd. Pte. in Singapore. This follows increased activity that is being undertaken by the group within the A-Star Institutes, and will allow further commercial exploits to be undertaken in the Eastern based markets.

    The venture builds on the increasing number of collaborations that have been undertaken with the A-Star institutes, including the Institu te for Microelectronics, (IME), the Singapore Institute for Manufacturing Technologies (SIMTech) and the Genome Institute of Singapore (GIS), and looks to develop further links with commercial partners based in Asia.

    Based in Singapore's world class research complex, Biopolis, QMDx Asia will initially focus on coordinating and expand work undertaken with all partners in Asia. QMDx Asia is expected to develop our group's commercial activities into key Asian markets and strengthen our position in the Asia Pacific regions.

    About QuantuMDx Group

    QuantuMDx Group is one of the most exciting medical device biotechs to emerge from the UK.  With its headquarters at the International Centre for Life in Newcastle, UK and offices in the USA, Asia and Africa, the last 5 years has seen the company grow from its humble beginnings in a South of England based 'biotech garage lab' to a multi-national company with pan-global collaborations, partnerships and even its own commercial genomics lab. Combining the business acumen of health professional and entrepreneur CEO Elaine Warburton with the far-reaching vision of inventor and CSO Jonathan O'Halloran and the clinical and ethical guidance of Prof Sir John Burn, the company has developed a suite of proprietary on-chip, molecular diagnostic and sequencing technologies – sample prep, DNA extraction, PCR and detection using a nanowire biosensor - which it is currently integrating into a suite of handheld and benchtop devices for rapid, accurate and very low cost assays for genomic and infectious disease applications along with its  "Last-Gen" T2T sequencer (telomere to telomere whole genome sequencing)

    For Further Information:

    QuantuMDx Contact:
    Elaine Warburton, Chief Executive Officer
    Tel: +44 7912 206 106
    Email: elaine.warburton@quantumdx.com

    QuantuMDx Asia Ltd Pte Contact:

    Miss Eunice Teo
    Tel. +65 91121 504

    Email: eunice.teo@quantumdx.com
  • Find news about QPOC 26th March 2012 | QMDx signs research collaboration agreement with IME, Singapore.

    View the press release

  • Find news about QPOC 17th January 2012 | 'A QuantuMDx Leap for Handheld DNA Sequencing' - Article in Bio-IT World

    Read Article

  • Find news about QPOC 9th November 2011 | QuantuMDx was presented with Best Innovation and Best Technology awards at the CELS
    Business for Life Awards 2011

    QuantuMDx was presented with Best Innovation and Best Technology awards at the CELS Business for Life Awards 2011 hosted in Newcastle Football Club's stadium at St James's Park. The evening was rounded off by QuantuMDx's Medical Director Prof Sir John Burn also winning the Lifetime Achievement award for services to science and medicine.

    The awards ceremony, which recognises and celebrates the healthcare and life sciences economy in the North East of England, was opened by Mike Nicholds, Managing Director of CELS. The keynote speaker was Jo Pisani, Global Pharmaceutical & Life Sciences Partner at PriceWaterhouseCoopers. Wendy Gibson from BBC TV hosted the evening with enthusiasm and humour.

    QuantuMDx's awards were received in recognition of the company's pioneering and groundbreaking work in developing a handheld all-in-one diagnostic device called QPOC™. The device, invented by Award winning team at Quantumdx

    QuantuMDx's chief scientific officer Jonathan O'Halloran, and currently in prototype, will eventually deliver affordable, rapid and accurate diagnostics to doctors and health professionals within minutes and at the patient's side.

    Elaine Warburton, chief executive commented "These awards are a real validation that we are truly on the road to success that will introduce our innovative technologies capable of addressing not only the major health challenges across the world such as HIV, TB and malaria but also provide cheap, rapid and accurate tests that will let your doctor diagnose your problems such as an infection, cancer or heart problems, within minutes. It will allow your doctor to prescribe you the right drug for you and your illness, first time. Eventually you'll see this technology on your supermarket or pharmacist's shelf for you to diagnose yourself at home with a mobile app linking you to your doctor for information, education and support!".

    View feature
  • Find news about QPOC 3th October 2011 | QuantuMDx signs an exclusive license agreement with Nanosys Inc

    QuantuMDx Group Limited today announced that it has signed an exclusive license agreement with Nanosys Inc., an advanced materials architect, for several patents and patent applications related to the use of nanostructures for biosensors.
    View press release

  • Find news about QPOC 22nd August 2011 | Dr Sam Whitehouse joins QMDx as Operations Director

  • Read news about QuantuMDx 15th August 2011 | QMDx opens new laboratory at International Centre for Life, Newcastle, UK

  • Latest news about QuantuMDx 8th August 2011 | QMDx closes on major funding round

  • QuantuMDx News 1st June 2011 | Three of QMDx's sequencing patents go to PCT

  • News about QuantuMDx 9th April 2011 | QMDx becomes industry partner of eSTI2 consortium developing mobile STI diagnostics

 
QuantuMDx DevicesQuantuMDx investment opportunitiesQuantuMDx Mission StatementQuanutMDx bio technololgyQuantuMDx developing new assays